Keytruda monotherapy non-inferior to chemotherapy in first-line gastric cancer

Merck said April 25 that Keytruda pembrolizumab as monotherapy met the primary endpoint of non-inferiority to standard-of-care chemotherapy in improving overall survival (OS) in the Phase III

Read the full 270 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE